BioSpace News Archive

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York.

Centogene N.V. announced that it received a notification letter dated March 27, 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth in Rule 5450 of the Nasdaq Listing Rules since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days.

Syros Pharmaceuticals announced the grant of a restricted stock unit award for 8,400 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros.

Oncoinvent AS announced the appointment of newly elected members of its Board of Directors and the formation of a Scientific and Clinical Advisory Board under the leadership of founding scientists Roy Larsen and Øyvind Bruland, previous board members and leading experts in oncology and pharmaceutical development.

Praxis Precision Medicines, Inc. announced that on April 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase 300 shares of its common stock and restricted stock unit awards covering 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan.

MediciNova, Inc. announced that an abstract regarding results of a clinical trial of MN-166 in glioblastoma has been selected for an oral presentation at the American Society of Clinical Oncology Annual Meeting to be held May 31 – June 4, 2024 in Chicago.

RemeGen Co. Ltd., a commercial-stage biotechnology company, obtained Fast Track Designation by the United States Food and Drug Administration recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept, independently developed by RemeGen for the treatment of patients with primary Sjögren’s syndrome.

Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported fourth quarter and full year 2023 financial results.

Fate Therapeutics, Inc. announced that on April 1, 2024 the Company granted restricted stock units representing 6,400 shares of its common stock to one newly-hired non-executive employee.

AstraZeneca and Daiichi Sankyo’s Biologics License Application for datopotamab deruxtecan has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor -positive, HER2-negative breast cancer who have received prior systemic therapy for unresectable or metastatic disease.